Stellar Biotech Inc (SBOTF) 0.6839 $SBOTF Stell
Post# of 273257
Posted On: 07/11/2015 6:33:18 PM
Stellar Biotech Inc (SBOTF) 0.6839 $SBOTF
Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
Marketwired - Thu Jul 09, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
Marketwired - Mon Jun 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference
Marketwired - Wed May 27, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies' Immunology 2015 Poster Available Online
Marketwired - Fri May 15, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Expands Online Corporate Communications Channels
Marketwired - Thu May 14, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced that the Company is expanding its online corporate communications channels to include Twitter, Facebook, and Google+/YouTube.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Reports Second Quarter 2015 Financial Results
Marketwired - Mon May 11, 3:30PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Presents Poster at Immunology 2015 on the Immunogenicity of Different Forms and Preparations of KLH
Marketwired - Thu Apr 30, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Marketwired - Wed Apr 01, 1:00AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs" (ALTERNEXT PARIS: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology.
KLH.VN: 0.870 (+0.170)
First FDA Breakthrough Therapy Designation for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule
Marketwired - Tue Mar 10, 4:32PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" is encouraged that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Reports First Quarter 2015 Financial Results
Marketwired - Mon Feb 09, 7:30AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, announced financial results for the first quarter period ended December 31, 2014.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at Biotech Showcase(TM) 2015 Conference
Marketwired - Thu Jan 08, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at LD Micro Conference
Marketwired - Mon Nov 24, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the Company's management team will present at the upcoming LD Micro Conference on Tuesday, December 2 at 1:00 p.m. PST.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:55AM CST
Stellar Biotechnologies Reports Year-End 2014 Financial Results
Marketwired - Thu Nov 13, 9:17AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Marketwired - Tue Nov 11, 11:46AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Araclon Biotech SL ("Araclon" today announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease.
KLH.VN: 0.870 (+0.170)
Stellar Bio tech chief bids adieu
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:05PM CST
Stellar Biotechnologies Announces Resignation of CTO Effective December 10, 2014
Marketwired - Fri Nov 07, 12:30PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), today announced the resignation of chief technology officer Herbert Chow, Ph.D. He will be leaving the company on December 10, 2014 for personal reasons. Dr. Chow's responsibilities will be reassigned based on a mutually agreed transitional plan.
KLH.VN: 0.870 (+0.170)
Stellar Bio reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:52AM CST
Stellar Biotechnologies Announces Year-End 2014 Conference Call
Marketwired - Thu Nov 06, 7:32AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , will host its year-end 2014 conference call and webcast at 1:30 PM ET (10:30 AM PT) on November 13, 2014.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma
Marketwired - Thu Oct 23, 1:16PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Biovest International, Inc. ("Biovest" today announced that the companies have executed a definitive supply agreement to meet Biovest's requirements for Keyhole Limpet Hemocyanin (KLH) for use in Biovest's BiovaxID(R) active immunotherapy to treat follicular non-Hodgkin's lymphoma.
KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
Marketwired - Thu Jul 09, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
Marketwired - Mon Jun 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference
Marketwired - Wed May 27, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies' Immunology 2015 Poster Available Online
Marketwired - Fri May 15, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Expands Online Corporate Communications Channels
Marketwired - Thu May 14, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced that the Company is expanding its online corporate communications channels to include Twitter, Facebook, and Google+/YouTube. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Reports Second Quarter 2015 Financial Results
Marketwired - Mon May 11, 3:30PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Presents Poster at Immunology 2015 on the Immunogenicity of Different Forms and Preparations of KLH
Marketwired - Thu Apr 30, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Marketwired - Wed Apr 01, 1:00AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs" (ALTERNEXT PARIS: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology. KLH.VN: 0.870 (+0.170)
First FDA Breakthrough Therapy Designation for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule
Marketwired - Tue Mar 10, 4:32PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" is encouraged that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies Reports First Quarter 2015 Financial Results
Marketwired - Mon Feb 09, 7:30AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, announced financial results for the first quarter period ended December 31, 2014. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at Biotech Showcase(TM) 2015 Conference
Marketwired - Thu Jan 08, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies to Present at LD Micro Conference
Marketwired - Mon Nov 24, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the Company's management team will present at the upcoming LD Micro Conference on Tuesday, December 2 at 1:00 p.m. PST. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:55AM CST
Stellar Biotechnologies Reports Year-End 2014 Financial Results
Marketwired - Thu Nov 13, 9:17AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Marketwired - Tue Nov 11, 11:46AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) and Araclon Biotech SL ("Araclon" today announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease. KLH.VN: 0.870 (+0.170)
Stellar Bio tech chief bids adieu
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:05PM CST
Stellar Biotechnologies Announces Resignation of CTO Effective December 10, 2014
Marketwired - Fri Nov 07, 12:30PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), today announced the resignation of chief technology officer Herbert Chow, Ph.D. He will be leaving the company on December 10, 2014 for personal reasons. Dr. Chow's responsibilities will be reassigned based on a mutually agreed transitional plan. KLH.VN: 0.870 (+0.170)
Stellar Bio reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:52AM CST
Stellar Biotechnologies Announces Year-End 2014 Conference Call
Marketwired - Thu Nov 06, 7:32AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , will host its year-end 2014 conference call and webcast at 1:30 PM ET (10:30 AM PT) on November 13, 2014. KLH.VN: 0.870 (+0.170)
Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma
Marketwired - Thu Oct 23, 1:16PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) and Biovest International, Inc. ("Biovest" today announced that the companies have executed a definitive supply agreement to meet Biovest's requirements for Keyhole Limpet Hemocyanin (KLH) for use in Biovest's BiovaxID(R) active immunotherapy to treat follicular non-Hodgkin's lymphoma. KLH.VN: 0.870 (+0.170)
(0)
(0)Scroll down for more posts ▼